Shyangdan, D <br/><br/>
Liraglutide for the treatment of type 2 diabetes.  [electronic resource] 

 -  Health technology assessment (Winchester, England)  May 2011 
 - 77-86 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>2046-4924 
<br/><br/><label>Standard No.: </label>10.3310/hta15suppl1/09  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Clinical Trials, Phase III as Topic<br/>Cost-Benefit Analysis<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Drug Therapy, Combination<br/>Glucagon-Like Peptide 1--administration & dosage<br/>Glycated Hemoglobin<br/>Humans<br/>Hypoglycemic Agents--administration & dosage<br/>Liraglutide<br/>Meta-Analysis as Topic<br/>Metformin--therapeutic use<br/>Multicenter Studies as Topic<br/>Quality-Adjusted Life Years<br/>Randomized Controlled Trials as Topic<br/>Weight Loss